Global Call for Asbestos Hazardous Waste Management Strategies
A new report in the Journal of Environmental Management warns that asbestos-bans should be supported by coordinated asbestos hazardous waste management strategies. Asbestos is classified as a Class I Carcinogen by the International Agency for Research on Cancer (IARC). Sixty countries have bans on asbestos. The US, China, India, and Russia are not among them. Nonetheless, asbestos is still part of the daily life of the population as asbestos-containing materials (ACMs) are still present in many buildings constructed and renovated before the 1990s. Asbestos has been used by many automobile, construction, manufacturing, power, and chemical industries for many years. Asbestos was a popular insulator because it resists heat and flame. The identification and coordinated management of asbestos hazardous waste is … Continue reading Global Call for Asbestos Hazardous Waste Management Strategies
Stories from Wives and Caregivers of People with Mesothelioma
A new Australian study looked at people who took care of mesothelioma patients. The study found that caretakers needed different types of support. Mesothelioma is a cancer caused by exposure to asbestos. Patients with mesothelioma, and their caregivers, are known to have some of the highest unmet needs of all cancer populations. Researchers talked to fourteen caregivers recruited from the Asbestos Diseases Foundation of Australia (ADFA). Of those interviewed, 13 were wives, and one was a daughter. Seven were retired at the time of the patients’ mesothelioma diagnosis, and 4 stopped work to provide care. Researchers used the feedback to assess best practices for follow-up care for mesothelioma. They now plan to share these best practices with clinicians across the … Continue reading Stories from Wives and Caregivers of People with Mesothelioma
Genomic Experts Report Most Complete Picture of Mesothelioma to Date
Australian and American genomic experts have completed a key step in improving the treatment of pleural mesothelioma. A new study gives results from a large study of malignant pleural mesothelioma Pleural mesothelioma is a type of cancer that develops on the thin layer of tissue that covers the lungs and chest wall. Asbestos causes mesothelioma and other asbestos-related diseases. Asbestos was used in thousands of industrial, commercial, construction, automotive, and consumer products. Pleural mesothelioma occurs in about 2,000 people in the United States every year. Scientists at the National Centre for Asbestos-Related Disease have taken a dramatic leap forward in the understanding of pleural mesothelioma. DNA Genes Impact Personalized Treatment Plans Previous genomic studies of malignant pleural mesothelioma were limited. … Continue reading Genomic Experts Report Most Complete Picture of Mesothelioma to Date
Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
Canadian researchers say radiotherapy may hold the key to improving outcomes in mesothelioma. Mesothelioma is a fast-growing membrane cancer caused by asbestos. Doctors have not found a single therapy that can beat it. For most patients, a combination of treatments offer the best survival odds. Pembrolizumab plus Radiotherapy Pleural mesothelioma is a rare lung-related cancer caused by asbestos exposure. There is no cure for mesothelioma. Most mesothelioma patients have a combination of therapies. Radiation is one of the methods doctors use to help slow its spread. Outcomes in mesothelioma vary widely with the use of radiotherapy. Pembrolizumab is used in combination with chemotherapy as a first-line treatment for mesothelioma. Radiotherapy uses beams of intense energy to kill cancer cells. One … Continue reading Radiotherapy Outcomes in Mesothelioma Linked to Pembrolizumab
Bevacizumab: An Immune Therapy in Mesothelioma Treatment
Bevacizumab, an immune therapy, enhances the immune system to target cancer cells. Historically, chemotherapy drugs were considered the standard treatment. But, a new study highlights bevacizumab, an immune therapy. It can now be considered in combination with mesothelioma treatments where accessible. Chemotherapy has been a popular treatment therapy. Cytotoxic chemotherapy uses anti-cancer (cytotoxic) drugs to destroy cancer cells. It results in a modest improvement in patient survival. But toxicity limits the eligible patient population. Targeted Chemotherapy Agents Immunotherapies are now playing a greater role in the treatment of many cancers. The last decade has presented a paradigm shift. There has been a change in the way we understand the relationship between the immune system and cancer progression. Several targeted agents … Continue reading Bevacizumab: An Immune Therapy in Mesothelioma Treatment
Mesothelioma Surveillance Protocols, Quality of Life, and Patient Hope
Mesothelioma surveillance protocols are a series of medical tests. Surveillance is designed to detect and track cancer progression. Surveillance protocols also check treatment effectiveness. And they provide patients with reassurance and hope. A new study identified the effectiveness of mesothelioma surveillance protocols. This study focused on patients who have noncurative treatment intent. Importance of Reassurance and Hope Findings from nine different studies identified the need for reassurance and hope as part of surveillance. They also highlighted the importance of trust and relationships. Follow-up and surveillance models provide patients with continuity, reassurance, and updates on condition. Continuity ensured patients knew who to contact if they had a new symptom or concern. Patient hopes for follow-up were for management of pain and … Continue reading Mesothelioma Surveillance Protocols, Quality of Life, and Patient Hope
Research Advancements Audit by Asbestos Diseases Research Institute
Research advancements provide a brighter future for malignant pleural mesothelioma patients. Pleural mesothelioma is an aggressive cancer of the lung lining. Mesothelioma is associated with asbestos exposure. Australian researchers from the Asbestos Diseases Research Institute and the University of Sydney have reviewed the basic research advancements. Their new publication covers mesothelioma biomarkers and treatment strategies. There is a long latency period from asbestos exposure to cancer development. A lack of genetic biomarkers makes early diagnosis difficult. The prognosis of pleural mesothelioma is poor. There is an average survival of eight to fourteen months following diagnosis. Diagnostic Biomarkers Biomarkers are limited in the clinic to diagnose pleural mesothelioma. A biomarker is a biological molecule found in blood or other body fluids … Continue reading Research Advancements Audit by Asbestos Diseases Research Institute
Asbestos Cement Roofing Poses an Ongoing Risk for Mesothelioma
Australian researchers have a warning for people in homes with asbestos cement roofing: Replace your roof or risk mesothelioma in the future. Michael Kottek and Man Lee Yuen are with the Asbestos Diseases Research Institute in Sydney. They recently published a new report on the risk of mesothelioma from roof tiles made of asbestos. Like all asbestos-containing products, asbestos cement roofing breaks down over time. Disintegrating or “friable” asbestos is the number one cause of deadly malignant mesothelioma worldwide. Writing in the American Journal of Industrial Medicine, Kottek and Yuen say buildings with roofs made from asbestos pose an ongoing threat to occupants, even if the tiles are not disturbed. Asbestos-Containing Products and Asbestos Cancer There was a time when … Continue reading Asbestos Cement Roofing Poses an Ongoing Risk for Mesothelioma
Genetic Mesothelioma Risk May Lead to Shorter Latency
A particular genetic risk for mesothelioma may be behind the few cases where cancer develops just a few years after asbestos exposure. That is the word from researchers at Australia’s Flinders University and the Asbestos Diseases Research Institute. Latency is the time it takes after exposure to a cancer-causing agent for signs of cancer to show up. Malignant mesothelioma has one of the longest latency periods of any cancer. In most cases, it takes about 40 years for mesothelioma to develop. As a result, mesothelioma is rare in people under 65. But, in rare cases, mesothelioma develops earlier in life. These cases have sometimes been dismissed as being unrelated to asbestos. But in a new journal article, mesothelioma experts from … Continue reading Genetic Mesothelioma Risk May Lead to Shorter Latency
New Mesothelioma Grading System: A Better Path to Prognosis?
A team of Australian researchers have developed a new mesothelioma grading system they believe is a more accurate method for predicting outcomes. The system assigns weighted scores based on things like mesothelioma subtype, the shape of the nuclei, BAP1 loss and other parameters. A higher score suggests the patient’s mesothelioma case may be more challenging to treat. Tests of the system in more than 350 patients show that it is highly accurate. The team lays out their new mesothelioma grading system in a recent issue of the American Journal of Surgical Pathology. In the article, they make the case for why this new prognostic tool could be a helpful supplement to the current, more widely-used WHO system. The Importance of … Continue reading New Mesothelioma Grading System: A Better Path to Prognosis?
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!